Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Rein Therapeutics (RNTX) Other financing activities (2016 - 2017)

Rein Therapeutics filings provide 2 years of Other financing activities readings, the most recent being $255000.0 for Q4 2017.

For the quarter ending Q4 2017, Other financing activities rose 54.55% year-over-year to $255000.0, compared with a TTM value of $165000.0 through Dec 2017, changed N/A, and an annual FY2017 reading of $2.3 million, up 1180.0% over the prior year.
Other financing activities hit $255000.0 in Q4 2017 for Rein Therapeutics, down from $1.6 million in the prior quarter.
The five-year high for Other financing activities was $1.6 million in Q3 2017, with the low at -$1.9 million in Q2 2017.